The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Sigachi Industries Limited, a leading player in the pharmaceutical industry, is establishing a R&D Center in Hyderabad, bringing its critical API developments and Analytical Efforts under one roof.
This strategic initiative involves an investment of up to US $1 million and is set to commence immediately, reinforcing Sigachi's commitment to innovation and long-term growth and efficiency.
The company is intensifying its R&D investments to drive high-value innovation and looking to fuel additional 6 CEP’s in the coming 6 months. These strategic investments will not only support the development of existing and new molecules but also reinforce Sigachi’s long-term growth trajectory, ensuring sustained profitability and market leadership.
The new facility is designed to: Optimize API production by integrating advanced systems and adhering to stringent global regulatory standards, ensuring high-quality outputs that meet international benchmarks; Drive sustainable growth by expanding the company’s development pipeline and accelerating R&D progress with a dedicated investment of up to US $1 million; Nurture talent by employing a team of 15-20 skilled R&D scientists dedicated to accelerating product development for regulated markets; and streamlining pharma product portfolio to focus on priority APIs and Intermediates.
Commenting on this development, Amit Raj Sinha, Managing Director and CEO, Sigachi Industries Limited said, "We have made significant progress by delivering Active Pharmaceutical Ingredients (APIs) to the pharmaceutical market. Our increased commitment to R&D is a clear testament to our strategic vision for innovation and excellence. By deepening our investments in R&D, we are not only accelerating our development efforts but also reinforcing our long-term growth objectives and strengthening Sigachi’s overall pipeline.”
Subscribe To Our Newsletter & Stay Updated